Why Juno Therapeutics Shares Vaulted 46% Higher in August – Madison.com
Madison.com |
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Madison.com The Kite Pharma deal comes ahead of an expected FDA decision on its CAR–T, axi-cel, on Nov. 29. It's not a given that axi-cel will get a green light, but it delivered a better than 50% complete response rate in trials, and the FDA opted against holding … |
